IZBA (travoprost) · Novartis
IZBA is FDA-approved to treat 2 conditions (same as IDOSE TR).
Details
- Status
- Discontinued
- First Approved
- 2014-05-15
- Patent Cliff
- 2029
- Routes
- OPHTHALMIC
- Dosage Forms
- SOLUTION/DROPS
IZBA Approval History
What IZBA Treats
2 indicationsIZBA is approved for 2 conditions since its original approval in 2014. These indications span multiple therapeutic areas including oncology, immunology, and more.
Same approved indications as IDOSE TR (same active ingredient).
Novartis's other novel FDA approvals
Other CDER-designated drugs from the same sponsor (2016–2025).
Clinical Trial Registry
8 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT02390284 STOP-RGCD results posted | 20140587 R01EY014957 | Ph 3 | terminated | Stop Retinal Ganglion Cell Dysfunction Study |
| NCT04615403 results posted | IDOS-106-EXCH | Ph 2 | completed | Study of Exchange of Travoprost Intraocular Implant |
| NCT01444040 | GCF-027 | Ph 4 | completed | Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent Inject) or Travoprost |
| NCT02914509 results posted | OTX-16-002 | Ph 3 | completed | Phase 3 Study Evaluating Safety and Efficacy of OTX-TP in Subjects With OAG or OHT |
| NCT01443988 | GCF-022 | Ph 4 | completed | Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent)or Travoprost |
| NCT01315574 BAK results posted | 11-007H | Ph 4 | terminated | Effects of Anti-Glaucoma Medications on the Ocular Surface |
| NCT02105311 | EC57-020-02-1 | Ph 4 | completed | Effect of Selective Laser Trabeculoplasty Versus Travoprost on Circardian Intraocular Pressure |
| NCT00705757 results posted | Pfizer GA6111AX | Ph 4 | completed | The Effects of Xalatan, Travatan and Lumigan on Skin Pigmentation Near the Eye |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
IZBA FDA Label Details
Indications & Usage
FDA Label (PDF)IZBA is FDA-approved to treat 2 conditions — same approved indications as IDOSE TR.
Pro Intelligence Preview
Deep insights for IZBA
Revenue Insights
- • Quarterly revenue tracking
- • Historical trend analysis
Patent Timeline
- • Cliff: 2029
- • 4 active patents
Trial Analysis
- • Clinical trial tracking
- • Development stage analysis
Competitive Landscape
- • Competitor tracking
- • Same target/indication analysis
Full approval history • All patents • Revenue trends • Competitor analysis
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.